The timing of the sale varies depending on the results of the Supreme Court's lawsuit against the validity of the patent. Hanmi has been approved for the first time in Korea as a generic for Galvusmet, a diabetes complex affiliated with Novartis' DPP-4 inhibitor.

Hanmi developed Vildagliptin HCl and licensed both single and multi-drugs including Vilagliptin. Attention is focusing on whether it will preoccupy markets as it has made efforts to commercialize them early. The MFDS approved Hanmi's Metformin HCl-Vildagliptin HCl.

Vildaglmet is the first generic for Galvusmet to be licensed in March 2008. It contains the same Vildagliptin HCl as the single Vildagle approved by Hanmi in February